Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.
Renal Department, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
ANZ J Surg. 2022 Nov;92(11):2996-3003. doi: 10.1111/ans.18037. Epub 2022 Sep 21.
Potential organ donors with primary brain tumours (PBT) frequently donate, however some may be declined due to uncertainty about tumour classification or transmission risk to transplant recipients. We sought to describe transmission risk and donation outcome of potential donors with PBT, including identifying missed opportunities for transplantation, and any PBT transmission events.
We undertook a population-based cohort study in NSW of all potential donors 2010-2015. PBT potential donors were characterized according to tumour grade and transmission risk, and whether they donated organs. Data linkage was used to determine agreement of risk assessment of potential donors to that in the Biovigilance Register, and to identify any PBT transmissions.
Of 2957 potential donors, 76 (3%) had PBTs. There was agreement of risk assessment in 44 (58%) cases. PBT potential donors had fewer comorbidities (1.6 vs. 2.1, P = 0.006) than non-PBT potential donors. Forty-eight (63%) potential donors were declined for non-PBT reasons, 18 (24%) were declined because of perceived PBT transmission risk and 10 (13%) donated. All PBT donors had WHO-I or -II tumours, and none had a ventriculo-pertioneal shunt. No transmission events occurred.
Donors with WHO-I/II PBT appear to have minimal risk of tumour transmission in solid organ transplantation; it is reassuring that no PBT transmission occurred. There is evidence of risk aversion to referrals with WHO-III/IV tumours. There exists opportunity to improve potential donor risk assessment at the time of referral using integrated data sets, and to increase organ donation and transplantation rates through greater utilization of PBT referrals.
原发性脑肿瘤(PBT)的潜在器官捐献者经常会捐献器官,但由于对肿瘤分类或向移植受者传播风险的不确定性,一些捐献者可能会被拒绝。我们旨在描述 PBT 潜在供者的传播风险和捐献结果,包括确定移植的错失机会,以及任何 PBT 传播事件。
我们在新南威尔士州开展了一项针对所有潜在供者(2010-2015 年)的基于人群的队列研究。根据肿瘤分级和传播风险以及是否捐献器官,对 PBT 潜在供者进行特征描述。通过数据链接,确定潜在供者风险评估与生物监测登记处的评估是否一致,并确定是否有任何 PBT 传播事件。
在 2957 名潜在供者中,有 76 名(3%)患有 PBT。44 名(58%)病例的风险评估一致。PBT 潜在供者的合并症较少(1.6 比 2.1,P=0.006)。48 名(63%)潜在供者因非 PBT 原因被拒绝,18 名(24%)因认为 PBT 传播风险而被拒绝,10 名(13%)捐献。所有 PBT 供者均为 WHO-I 或 -II 肿瘤,均无脑室-腹膜分流术。没有发生传播事件。
在实体器官移植中,WHO-I/II PBT 供者似乎传播肿瘤的风险极小;令人放心的是,没有发生 PBT 传播。对于 WHO-III/IV 肿瘤的转诊,存在风险规避的证据。通过更好地利用 PBT 转诊,在转诊时使用综合数据集来改进潜在供者的风险评估,并提高器官捐献和移植率,是有机会的。